Junshi Biosciences Announces Approval for Marketing of VV116 in China
SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Pharmaceutical
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic...
eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader...
Lumanity Expands Medical Affairs Capabilities
LUMANITY EXPANDS MEDICAL AFFAIRS CAPABILITIES Enhanced solutions to deliver effective medical strategies, cross-functional communication plans, and programs to connect with...
scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
Commercial launch planned for February 20, 2023BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical...
Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer
NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
Quarterly investor call and webcast scheduled on Monday, February 13 at 8:00 a.m. ETRoivant will also participate in the SVB...
Survey demonstrates that individuals with COPD seek more options to reduce risks of seasonal respiratory viral infections
-- ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce...
AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Study designed to optimize treatment regimen and evaluate efficacy over six-month dosing period Initial results expected in second half of...
Ring Therapeutics Announces Appointment of Industry Veteran Christopher Wright, M.D., Ph.D. as Chief Medical Officer, Head of Translational Research
CAMBRIDGE, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize...
Achieve Life Sciences Announces Granting of New Hire Inducement Award
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage...
Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders
PHILADELPHIA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)...
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023...
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
Presentation on Thursday, February 2, 2023 at 2:00 PM ET ANAHEIM, CA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc....
Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
Preclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin’s lymphomas, and significantly better performance...
Release date of annual report 2022 for ALK and audio cast
On Friday, 3 February 2023 expectedly around noon, ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its annual report...
Amarin to Present at SVB Securities Global Biopharma Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail,...
Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer
Rob Brown to continue serving as a member of the Board of Directors and as a special advisor to the...
Recce Pharmaceuticals Receives A$6.21 Million from Research and Development (R&D) Rebate Payments
SYDNEY, Australia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing...
Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model
Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments,...